Overview

Long-term Treatment Study of Certolizumab Pegol Without Coadministration of Methotrexate in Japanese Rheumatoid Arthritis (RA) Patients

Status:
Completed

Trial end date:
2013-05-01

Target enrollment:

Participant gender:

Summary

The objectives of this study are to evaluate the safety and efficacy of certolizumab pegol when administered without coadministration of methotrexate over the long term in Japanese RA patients who transferred from Study 275-08-003 (NCT00791921), and to evaluate the effects of different dosing regimens on the safety and efficacy of certolizumab pegol in American College of Rheumatology 20% (ACR20) responders who completed Study 275-08-003.

Phase:

Phase 3

Details

Lead Sponsor:

Astellas Pharma Inc

Collaborator:

UCB Japan Co. Ltd.

Treatments:

Certolizumab Pegol
Methotrexate